Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2424-2430

  Shirahama, Tsutomu ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2;

ARTICLE; CANCER INVASION; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

AGED; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HUMANS; IMMUNOBLOTTING; ISOENZYMES; MEMBRANE PROTEINS; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; UP-REGULATION; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0034099597     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Shiff, S. J., and Rigas, B. Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology, 113: 1992-1998, 1997.
2. Kujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W., and Herschman, H. R. TIS10, a phorbor ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/ cyclooxygenase homologue. J. Biol. Chem., 266: 12866-12872, 1991.
3. O'Banion, M. K., Sadowsky, H. B., Winn, V., and Young, D. A. A serum-and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J. Biol. Chem., 266: 23261-23267, 1991.
4. DuBois, R. N., Awad, J., Morrow, J., Roberts, L. J., II, and Bishop, P. R. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-α and phorbol ester. J. Clin. Invest., 93: 493-498, 1994.
5. Jones, D. A., Carlton, D. P., McIntyre, T. M., Zimmerman, G. A., and Prescott, S. M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J. Biol. Chem., 268: 9049-9054, 1993.
6. Xie, W., and Herschman, H. R. V-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. J. Biol. Chem., 270: 27622-27628, 1995.
7. Thun, M. J., Namboodiri, M. M., and Heath, G. W. Aspirin use and reduced risk of fatal colon cancer. N. Eng. J. Med., 325: 1593-1596, 1991.
8. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celand, P., Booker, S. V., Robinson, R., and Offerhaus, G. J. A. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Eng. J. Med., 328: 1313-1316, 1993.
9. Giovannucci, E., Egan, K. M., Hunter, D. J., Stampfer, M. J., Colditz, G. A., Willett, W. C., and Speizer, F. E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med., 333: 609-614, 1995.
10. Reddy, B. S., Rao, C. V., and Seibert, K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res., 56: 4566-4569, 1996.
11. Sheng, H., Shao, J., Kirkland, S. C., Isakson, P., Coffey, R. J., Morrow, J., Beauchamp, R. D., and Dubois, R. N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest., 99: 2254-2259, 1997.
12. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
13. Ristimaki, A., Honkanen, N., Jankala, H., Sipponen, P., and Harkonen, M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res., 57: 1276-1280, 1997.
14. Wolff, H., Saukkonen, K., Anttila, S., Karjalainen, A., Vainio, H., and Ristimaki, A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res., 58: 4997-5001, 1998.
15. Tucker, O. N., Dannenberg, A. J., Yang, E. K., Zhang, F., Teng, L., Daly, J. M., Soslow, R. A., Masferrer, J. L., Woerner, B. M., Koki, A. T., and Fahey, T. J., III. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res., 59: 987-990, 1999.
16. Silverman, D. T., Hartge, P., Morrison, A. S., and Devesa, S. S. Epidemiology of bladder cancer. Hematol. Oncol. Clin. N. Am., 6: 1-30, 1992.
17. Michaud, D. S., Spiegelman, D., Clinton, S. K., Rim, E. B., Curhan, G. C., Willett, W. C., and Giovannucci, E. L. Fluid intake and the risk of bladder cancer in men. N. Engl. J. Med., 340: 1390-1397, 1999.
18. Case, R. A., Hosker, M. E., McDonald, D. B., and Pearson, J. T. Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. Br. J. Ind. Med., 11: 75-104, 1954.
19. Sorlie, T., Mattel, P. G., Hainaut, P., Lewalter, J., Holm, R., Borresen, D. A. L., and Montesano, R. Analysis of p53, p16MTS, p21WAF1 and H-ras in archived bladder tumors from workers exposed to aromatic amines. Br. J. Cancer, 77: 1573-1579, 1998.
20. Ozen, H. Bladder cancer. Curr. Opin. Oncol., 10: 273-278, 1998.
21. Subbaramaiah, K., Zakim, D., Weksler, B. B., and Dannenberg, A. J. Inhibition of cyclooxygenase: a novel approach to cancer prevention. Exp. Biol. Med., 216: 201-210, 1997.
22. Sakata, T., Hasegawa, R., Johansson, S. L., Zenser, T. V., and Cohen, S. M. Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl-]formamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in male F344 rats. Cancer Res., 46: 3903-3906, 1986.
23. Shibata, M., Hasegawa, R., Shirai, T., Takesada, Y., and Fukushima, S. Chemoprevention by indomethacin of tumor promotion in a rat urinary bladder carcinogenesis model. Int. J. Cancer, 55: 1011-1017, 1993.
24. Okajima, E., Denda, A., Ozono, S., Takahama, M., Akai, H., Sasaki, Y., Kitayama, W., Wakabayashi, K., and Konishi, Y. Chemo-preventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res., 58: 3028-3031, 1998.
25. Baithun, S. I., Rogers, H. S., Martin, J. E., Zuk, R. J., and Blandy, J. P. Primary dysplasia of bladder. Lancet, ii: 483, 1988.
26. Cheng, L., Cheville, J. C., Neuman, R. M., and Bostwick, D. G. Natural history of urothelial dysplasia of the bladder. Am. J. Surg. Pathol., 23: 443-447, 1999.
27. The Japanese Urological Association and the Japanese Society of Pathology. General Rule for Clinical and Pathological Studies on Bladder Cancer, 2nd ed. Tokyo: Kanehara Publishers B. V., 1993.
28. Epstein, J. I., Amin, M. B., Reuter, V. R., Mostofi, F. K., and The Bladder Consensus Conference Committee. The WHO/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am. J. Surg. Pathol., 22: 1435-1448, 1998.
29. Tsujii, M., and DuBois, R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell, 83: 493-501, 1995.
30. Bradford, A. A rapid and sensitive method for the quantitation of microgram quantities for protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
31. Subbaramaiah, K., Telang, N., Ramonetti, J. T., Araki, R., DeVito, B., Weksler, B. B., and Dannenberg, A. J. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res., 4424-4429, 1996.
32. Sheng, G. G., Shao, J., Sheng, H., Hooton, E. B., Isakson, P. C., Morrow, Coffey, R. J., Dubois, R. N., and Beauchamp, R. D. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology, 113: 1883-1891, 1997.
33. Rodenhuis, S., and Slebos, R. J. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res., 52: 2665-2669, 1992.
34. Vageli, D., Kiaris, H., Delakas, D., Anezinis, P., Cranidis, A., and Spandidos, D. A. Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors. Cancer Lett., 107: 241-247, 1996.
35. Denissenko, M. F., Pao, A., Tang, M., and Pfeifer, G. P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hot spots in p53. Science (Washington DC), 274: 430-432, 1996.
36. Elder, D. J. E., Halton, D. E., Hague, A., and Paraskeva, C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer Res., 3: 1679-1683, 1997.
37. Piazza, G. A., Rahm, A. K., Finn, T. S., Fryer, B. H., Li, H., Stoumen, A. L., Pamukcu, R., and Ahnen, D. J. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res., 57: 2452-2459. 1997.
38. Tsujii, M., Kawano, S., and Dubois, R. N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. USA, 94: 3336-3340, 1997.